
Over 25 companies advance 30+ myasthenia gravis drugs, reshaping treatment options.
More than 25 companies are actively developing over 30 drugs for myasthenia gravis, a chronic autoimmune disorder causing muscle weakness. Key therapies in late-stage trials include targeted biologics like Immunoglobulin G degraders and Complement fa...



